

Elena V Poddubskaya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/706508/publications.pdf>

Version: 2024-02-01

33
papers

16,507
citations

567281

15
h-index

454955

30
g-index

33
all docs

33
docs citations

33
times ranked

16314
citing authors

#	ARTICLE	IF	CITATIONS
1	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 165, 71-81.	2.0	9
2	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021, 152, 7-14.	2.0	40
3	Abnormal promoter DNA hypermethylation of the integrin, nidogen, and dystroglycan genes in breast cancer. <i>Scientific Reports</i> , 2021, 11, 2264.	3.3	12
4	RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual Biosamples. <i>Frontiers in Oncology</i> , 2021, 11, 732644.	2.8	6
5	Experimental and Meta-Analytic Validation of RNA Sequencing Signatures for Predicting Status of Microsatellite Instability. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 737821.	3.5	4
6	RNA sequencing for research and diagnostics in clinical oncology. <i>Seminars in Cancer Biology</i> , 2020, 60, 311-323.	9.6	56
7	RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens. <i>Biomedicines</i> , 2020, 8, 114.	3.2	22
8	Abnormal Hypermethylation of CpG Dinucleotides in Promoter Regions of Matrix Metalloproteinases Genes in Breast Cancer and its Relation to Epigenomic Subtypes and HER2 Overexpression. <i>Biomedicines</i> , 2020, 8, 116.	3.2	9
9	Diagnostic Value of Combinatorial Markers in Colorectal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 832.	2.8	8
10	RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004945.	1.2	26
11	Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1580.	4.1	17
12	Clinical use of RNA sequencing and onco-box analytics to predict personalized targeted therapeutic efficacy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13676-e13676.	1.6	7
13	Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21542-e21542.	1.6	0
14	Features of the management of cancer patients during the COVID-19 pandemic. <i>SeĀenovskij Vestnik</i> , 2020, 11, 62-73.	0.4	2
15	Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors. <i>Frontiers in Oncology</i> , 2019, 9, 1026.	2.8	15
16	Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003434.	1.2	27
17	High-Throughput Mutation Data Now Complement Transcriptomic Profiling: Advances in Molecular Pathway Activation Analysis Approach in Cancer Biology. <i>Cancer Informatics</i> , 2019, 18, 117693511983884.	1.9	13
18	Genome-wide methylotyping resolves breast cancer epigenetic heterogeneity and suggests novel therapeutic perspectives. <i>Epigenomics</i> , 2019, 11, 605-617.	2.1	26

#	ARTICLE	IF	CITATIONS
19	Oncobox, gene expression-based second opinion system for predicting response to treatment in advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, e13143-e13143.	1.6	11
20	Endocrine adverse events of immune checkpoint inhibitors: results of a single-center study. SeÅenovskij Vestnik, 2019, 10, 4-11.	0.4	1
21	RNA-sequencing and bioinformatic analysis to pre-assess sensitivity to targeted therapeutics in recurrent glioblastoma.. Journal of Clinical Oncology, 2019, 37, e13533-e13533.	1.6	0
22	Molecular pathway activation-based analysis for personalized prescription of tyrosine kinase inhibitors for advanced solid tumor patients.. Journal of Clinical Oncology, 2019, 37, e15636-e15636.	1.6	0
23	Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data. Cancers, 2018, 10, 365.	3.7	27
24	Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Experimental Hematology and Oncology, 2018, 7, 21.	5.0	40
25	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. International Journal of Cancer, 2018, 143, 2053-2064.	5.1	76
26	Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation. Oncotarget, 2018, 9, 5111-5124.	1.8	30
27	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq1 1 0.784314 mgBT /Ov	1.8	30
28	Activation of intracellular signaling pathways as a new type of biomarkers for selection of target anticancer drugs.. Journal of Clinical Oncology, 2017, 35, e23142-e23142.	1.6	14
29	Nivolumab versus Docetaxel in Advanced Squamous-Cell Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 123-135.	27.0	7,261
30	Nivolumab versus Docetaxel in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 1627-1639.	27.0	7,973
31	DNA methylation in the promoter regions of the laminin family genes in normal and breast carcinoma tissues. Molecular Biology, 2015, 49, 598-607.	1.3	9
32	A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8009-8009.	1.6	27
33	Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 344-344.	1.6	13